PremiumThe FlyInozyme downgraded to Neutral from Overweight at Piper Sandler Inozyme downgraded to Hold from Buy at Jefferies Leerink bullish on BioMarin following Inozyme deal, expects additional BD PremiumThe FlyBioMarin says Inozyme deal to strengthen enzyme therapies portfolio Inozyme downgraded to Neutral from Outperform at Wedbush Inozyme Pharma Merges with BioMarin for $270 Million PremiumThe FlyInozyme expects cash to fund operations into Q1 of 2026 INZY Earnings Report this Week: Is It a Buy, Ahead of Earnings? Promising Potential of INZ-701 in Treating ENPP1 Deficiency Drives Buy Rating for Inozyme Pharma 
